Interpace Diagnostics (IDXG) - Rein momentumgetriebener Anstieg mahnt zur Vorsicht - Seite 2

"The Company also anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to its commercial operations, developing products and product candidates, right sizing and reorganizing its administrative organization and winding down activities and managing obligations related to its discontinued operations."

Interpace hat also alleine im letzten Quartal 5 Mio. US-Dollar Cash im operativen Geschäft verbrannt.

Jetzt ist kaum noch Cash übrig:

"The company had cash balances of $1.7 million on September 30, 2016 and has negotiated a line of credit of up to $1.2 million and has not drawn down on the facility to date."

Das Unternehmen hat negatives Eigenkapital, ist also de facto überschuldet:

"The Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2016 reported total stockholders’ (deficit) equity of ($1,479,000)."

Das derzeitige operative Geschäft mit den obigen Krebstests ist vom alten Eigentümer auf Pump gekauft worden:

"On September 30, 2016, the Company, Interpace LLC, and the RedPath Equityholder Representative entered into an amendment to the $10.7 million interest free secured note payable to the former equity holders of RedPath to extend by one month, until November 1, 2016, subject to the terms of the amendment, the due date for the first quarterly payment of principal under the note."

"Under the note, the Company is required to make eight installment payments of principal, with each payment equal to $1,333,750, together with accrued and unpaid interest, if any."

Interpace schuldet RedPath also 10,7 Mio. US-Dollar, die man in jeweils acht Raten zu 1,3 Mio. Euro abstottern möchte.  

"The first quarterly payment of principal under the note originally was due on October 1, 2016 and the first payment is now due on December 31, 2016."

Bereits die erste Rate, die am 1.Oktober fällig war, konnte Interpace nicht begleichen. RedPath erklärte sich einverstanden, das Zahlungsziel auf 31.12.2016 zu verlängern.

"The Company currently has no means to make the first quarterly payment of principal due on December 31, 2016, and if the due date for the first quarterly payment of principal is not extended by the RedPath Equityholder Representative or other equity or debt capital is not raised, the RedPath Equityholder Representative could foreclose on the Company’s assets, force the Company into bankruptcy or pursue other remedies."